UCLA Dept. of Psychology/Division of Cancer Prevention and Control Research & Breastlink Medical Group
Are You a Woman Diagnosed with Breast Cancer?
Have you used a personal web page to communicate with friends or family about your experience with cancer?
Participate in Project Connect, a study to understand how women use personal web pages to communicate with others during breast cancer.
About the study:
- Complete one interview regarding your experience with your personal web page
- $40 compensation for completing the interview
Are you eligible?
- Diagnosed with breast cancer in the past five years
- Used a personal web page to communicate with others about your experience with cancer
- At least 18 years of age
- Comfortable completing interview in English
For more information about Project Connect, please contact: Dr. Annette Stanton, 310-825-9189; stanton.study@ucla.edu
Neoadjuvant
ACOSOG Z1031 – A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer.
Protocol Title: B-40
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens.
Description
If a participant meets the eligibility criteria and agrees to take part, she will be randomly assigned to one of six treatment groups. She will have an equal chance of being in any of the six groups. Participants will receive treatment every 3 weeks for approximately 6 months before undergoing either a lumpectomy or a mastectomy. Participants on three of the treatment arms will receive treatment with bevacizumab every 3 weeks for an additional 10 doses. more...
Adjuvant
SWOG S0221 – A Phase III Trial of Continuous Schedule AC + G vs Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Ca
ECOG – Program for the Assessment of Clinical Trial Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
Protocol Title: SO307
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer (SWOG S0307)
Description
The skeleton is the initial site of recurrence in 35-40% of patients with breast cancer. Up to 60-80% of metastatic breast cancer patients eventually develop signs and symptoms related to bone involvement. Bone metastases in breast cancer are associated with significant complications including pain, pathologic fractures, increased calcium levels, bone marrow suppression, and spinal cord compression. more...
Protocol Title: NSABP B-42
NSABP B-42 A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor(AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer.
Description
The main purpose of the study is to learn whether or not continuing hormonal therapy with an aromatase inhibitor (AI) called letrozole for 5 additional years after already taking 5 years of hormonal therapy can further reduce the chance of breast cancer returning. more...
Metastatic
Phase I-II Study of Denileukin Diftitox (ONTAK) in Patinets with Advanced Refractory Breast Cancer
For the current eligibility status of and additional information about any of these clinical studies, please contact the Barbara K. Robinson Breast Cancer Research Program at 1-562-981-6101.
Protocol Title: NUO7B1
A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer.
Description
This study is being done to compare the effects of paclitaxel given with sorafenib to paclitaxel given with a placebo for breast cancer which has recurred locally or spread to other parts of the body. Paclitaxel is a commonly used chemotherapy drug. Sorafenib is a new type of anti-cancer drug. A placebo does not contain any active medication and should not influence the effect of paclitaxel. Sorafenib may positively or negatively influence the effect of paclitaxel. Finding out what effect sorafenib might have is the purpose of this study. Participants will be randomly assigned to get either sorafenib with paclitaxel or placebo with paclitaxel; they will not get both treatments. more...
Protocol Title: BZL101
Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer (425-07)
Description
More than 60% of the drugs used to treat breast cancer are obtained from natural substances. Drugs made from plants have been used for centuries to treat cancer and cancer-related symptoms. With the exception of the drug class called taxanes made from the Pacific yew tree, botanical agents have not been tested in clinical trials to assess their safety and effectiveness in treating breast cancer. BZL101 is a Chinese medicine extract made from the herb Scutellaria Barbata or Chinese skullcap. Previously a water containing extract of Chinese skullcap was shown to inhibit the growth of breast cancer cells in a test tube. more...
Protocol Title: 438-07
An open-label, multi-centre study of lapatinib in combination with chemotherapy in patients with ErbB2 overexpressing breast cancer after trastuzumab failure in the neoadjuvant or adjuvant setting (438-07).
Description
ErbB2 is one member of a family of genes that provides instructions for producing proteins that stimulate cell growth and division. Patients with ErbB2 overexpressing breast cancer that has progressed during or within 6 months after completing treatment that included trastuzumab (Herceptin) for treatment of newly diagnosed breast cancer are likely resistant to trastuzumab. Preclinical data suggest that breast cancer that is resistant to trastuzumab may respond to treatment with lapatinib. Using lapatinib in combination with chemotherapy appears to be appropriate to study as combination therapy after being failed by trastuzumab.
The treatment in this study is lapatinib plus one of three chemotherapy drugs (capecitabine or docetaxel or nab paclitaxel). The chemotherapy to be used will be decided by the participant’s doctor. more...
Protocol Title: 1068
A Phase II Study of Sunitinib Malate Single Agent for the Treatment of Women with Advanced Breast Cancer
Description
Isolated recurrence of disease in the chest wall or regional lymph nodes (loco-regional recurrence) affects 10% to 35% of women with operable breast cancer after their primary treatment. more...
Protocol Title: AC01B07
A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic Breast Cancer that has Progressed During or After Bevacizumab Therapy
Description
This study is being done to compare the effects of gemcitabine given with sorafenib to gemcitabine given with a placebo for breast cancer which has recurred locally or spread to other parts of the body. more...
top... |
